Mid Cap Losers: IRNT, EDIT, NAVI
3:29 pm Wednesday, September 29th, 2021
Ironnet Inc (NYSE:IRNT) initiated with a Hold and a $27 price target at Jefferies, which believes that co’s collective defense model is a differentiated approach to network security enhancing protection via sharing security telemetry but which views the stock’s valuation as full at current levels. Sees continued volatility.
Editas Medicine Inc (NASDAQ:EDIT) drops to its lowest levels since early August after announcing initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101, which is in development for the treatment of blindness due to Leber congenital amaurosis 10. Among efficacy results, two of three subjects in the mid-dose cohort followed for up to six months showed efficacy signals suggesting productive editing and providing initial support for clinical benefits. Co is commencing treatment in the pediatric mid-dose cohort. Co hosted a webcast to further review the data earlier today.
Navient Corp (NASDAQ:NAVI) and Maximus (MMS) signed an agreement to transfer the loan servicing for US Department of Education-owned student loan accounts from co to Maximus through a contract novation; following receipt of necessary approvals, co would exit the Department of Education student loan servicing program. Drops to two-month lows.
